Upon completion of a one-year multicenter trial, 146 patients with severe
hypercholesterolemia and treated with atorvastatin 80 mg/day were entered into an open …

In this 2-year study, 787 patients with hypercholesterolemia received either atorvastatin 10
mg to 80 mg/day (623 patients) or lovastatin 20 mg to 80 mg/day (164 patients). Patients …

Objective Atorvastatin is a synthetic inhibitor of 3 唱 hydroxy 3 唱 methylglutaryl coenzyme A
(HMG 唱 CoA) reductase. It has a longer half life and longer duration of action than that of all …

Plasma cholesterol and other lipoproteins play a significant role in the development of
atherosclerosis and subsequent coronary heart disease (CHD). This 1 year study was …

Atorvastatin and simvastatin are both effective in lowering LDL-C and TC in hyperlipidemic
patients. The usual starting dose for both agents is 10 mg once daily, although for …

Background: Coronary heart disease (CHD) is the number one cause of death in Western
societies. Elevated levels of plasma low-density lipoprotein (LDL) cholesterol and triglycer …

Background: Atorvastatin is a synthetic inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase. In placebo-controlled trials, it has been shown to achieve significant …

Atorvastatin is a synthetic inhibitor of 3-hydroxy 3-methylglutaryl coenzyme A (HMG-CoA)
reductase inhibitor. It has a longer half life and longer duration of action than that of all other …

Preclinical and clinical data on atorvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase inhibitor, indicate that it has superior activity in treating a variety of …

Hyperlipidemia is a major risk factor for coronary heart disease (CHD). It is now well
established that reducing increased LDL-C levels can significantly reduce the risk of CHD …